Novartis (NYSE:NVS) posted its quarterly earnings results on Monday. The company reported $1.34 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.37 by ($0.03), MarketWatch Earnings reports. The company had revenue of $12.77 billion for the quarter, compared to the consensus estimate of $12.86 billion. Novartis had a net margin of 14.71% and a return on equity of 24.39%. Novartis’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.32 EPS.
Shares of Novartis stock traded down $2.07 on Wednesday, reaching $93.87. The stock had a trading volume of 242,282 shares, compared to its average volume of 2,095,250. Novartis has a 1 year low of $69.18 and a 1 year high of $99.84. The company has a market cap of $214.84 billion, a P/E ratio of 30.50, a price-to-earnings-growth ratio of 1.76 and a beta of 0.59. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.49. The business’s 50 day moving average is $93.10 and its two-hundred day moving average is $88.01.
A number of equities analysts have weighed in on NVS shares. Morgan Stanley reiterated an “overweight” rating on shares of Novartis in a research report on Friday, January 8th. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of Novartis in a research report on Tuesday, November 10th. Berenberg Bank started coverage on shares of Novartis in a research report on Tuesday, September 29th. They set a “buy” rating for the company. Barclays reiterated an “underweight” rating on shares of Novartis in a research report on Friday, January 22nd. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Novartis in a research report on Friday, January 15th. They set a “buy” rating for the company. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $114.00.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. Its Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, established, and cardiovascular, renal and metabolism medicine products.
Further Reading: Why do companies engage in swaps?
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.